Summary by Moomoo AI
SciSparc Ltd., a clinical-stage pharmaceutical company, has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP, on January 21, 2024. Under the SEPA, SciSparc may sell up to $20 million of its ordinary shares over the next three years at a 3% discount to the market price, subject to certain conditions including a cap on YA's ownership at 4.99% of SciSparc's shares. The agreement allows for pre-paid advances up to $5 million, with promissory notes maturing 24 months post-issuance and accruing interest at 5% per annum, increasing to 18% upon an event of default. Monthly installment payments begin 150 days after a note's issuance, with the option for SciSparc to pay in...Show More